The purpose of this study was to prepare conventional and stealth liposomes containing gemcitabine in an attempt to improve cytotoxic effect against various tumor, both stealth and conventional liposomes has been investigated by taking various molar ratios of lipids like DPPC, Cholesterol, DSPE-MPEG 2-K and prepared by TLE method and active pH gradient method, SUV were obtained by extrusion through sonicator and characterized for vesicle size range as (130±1 to 265±2.4 nm) and polydispersity index was found (0.11 to 0.625) indicating stable formulation. Entrapment efficiency of gemcitabine was improved by active pH gradient method results shown that stealth liposomes (SL-5) contain DPPC: cholesterol: DSPE-MPEG 2-K with molar ratio (6:2:0.2) improved up to 75.3% whereas only 59.7% by TLE method. Zeta potential was obtained for various formulations as the range of (-9.3±2.8 to -37.3±2.3) and in-vitro release studies for (CL-5) shows almost 85% drug release from vesicles after 48 hrs and 65% drug released from (SL-5) liposomes proved that ability to remain drug in prolong circulation by targeting desired tumor site. Release profile further treated for kinetic modeling for screening of mechanism of transport best fitted for Higuchi model with (R2) is (0.996 to 0.994) followed by anomalous (non-fickian) type transport with n value is (< 0.5) as per korsmeyer-Peppas models. Optimized formulation of stealth liposomes (SL-5) effective against human breast tumor cell line (MCF-7) compared with CL-5 and Pure drug. Cytotoxic effect is dose dependant and for SL-5 % control growth was observed about 20%. Incorporation of Gemcitabine into bilayers was determined by phase transition behaviour in DSC thermogram as well as FTIR study.
Loading....